{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:01:39Z","timestamp":1791568899184,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Long-acting injectable antiretroviral therapy (LAI-ART) is expected to improve health outcomes among persons with HIV. Yet, uptake has been slow and data on potential barriers to access are sparse. We used medication formulary data from state Medicaid and AIDS Drug Assistance Programs (ADAPs) to examine state-level variation in access to LAI-ART among uninsured and low-income persons with HIV. We identified substantial coverage gaps: cabotegravir\/rilpivirine was not covered without prior authorization by 26 state Medicaid programs and not covered at all by 15 state ADAPs; lenacapavir was not covered without prior authorization by 32 Medicaid programs and not covered at all by 18 ADAPs. As a result of these gaps, many US persons with HIV are currently unable to access LAI-ART. Policies that increase access are needed to ensure the equitable distribution of LAI-ART. As states work to reduce supply and payment chain barriers, the US Department of Health and Human Services, notably its Centers for Medicare &amp; Medicaid Services and the Health Resources and Services Administration, should provide increased federal assistance, guidance, and oversight to improve LAI-ART access among people with HIV.<\/jats:p>","DOI":"10.1093\/haschl\/qxaf016","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T10:04:42Z","timestamp":1738145082000},"source":"Crossref","is-referenced-by-count":4,"title":["State-level variation in access to long-acting injectable antiretroviral therapy for HIV in the United States"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7665-2230","authenticated-orcid":false,"given":"Lauren C","family":"Zalla","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 ,","place":["United States"]},{"name":"Department of General Internal Medicine, Johns Hopkins School of Medicine , Baltimore, MD 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Horn","sequence":"additional","affiliation":[{"name":"National Alliance of State and Territorial AIDS Directors , Washington DC 20001 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5380-2013","authenticated-orcid":false,"given":"Sita","family":"Lujintanon","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-2592","authenticated-orcid":false,"given":"Catherine R","family":"Lesko","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"2025022111124485100_qxaf016-B1","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2024"},{"issue":"7","key":"2025022111124485100_qxaf016-B2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"2025022111124485100_qxaf016-B3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting injectable cabotegravir\/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy","volume":"78","author":"Brock","year":"2024","journal-title":"Clin Infect Dis."},{"issue":"1","key":"2025022111124485100_qxaf016-B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000003396","article-title":"Feasibility of implementing a low-barrier long-acting injectable antiretroviral program for HIV treatment and prevention for people experiencing homelessness","volume":"96","author":"Mehtani","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"2025022111124485100_qxaf016-B5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1089\/apc.2024.0048","article-title":"Long-acting injectable ART in practice: a mixed methods implementation study assessing the feasibility of using LAI ART in high risk populations and at alternative low barrier care sites","volume":"38","author":"Fletcher","year":"2024","journal-title":"AIDS Patient Care STDs"},{"key":"2025022111124485100_qxaf016-B6","doi-asserted-by":"publisher","first-page":"232595822110090","DOI":"10.1177\/23259582211009011","article-title":"The promise of improved adherence with long-acting antiretroviral therapy: what are the data?","volume":"20","author":"Scarsi","year":"2021","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2025022111124485100_qxaf016-B7","article-title":"Medicaid and People with HIV. Kaiser Family Foundation","author":"Dawson","year":"2023"},{"key":"2025022111124485100_qxaf016-B8","article-title":"Ryan White HIV\/AIDS Program AIDS Drug Assistance Program (ADAP) Annual Client-Level Data Report, 2022","author":"Health Resources and Services Administration","year":"2024"},{"key":"2025022111124485100_qxaf016-B9","article-title":"Diagnoses of HIV Infection in the United States and Dependent Areas, 2021","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2025022111124485100_qxaf016-B10","article-title":"10 Things to know about Medicaid managed care. Kaiser Family Foundation","author":"Hinton","year":"2024"},{"key":"2025022111124485100_qxaf016-B11","article-title":"National RWHAP Part B ADAP monitoring project annual report","author":"National Alliance of State and Territorial AIDS Directors (NASTAD)","year":"2024"},{"issue":"3","key":"2025022111124485100_qxaf016-B12","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis."},{"issue":"Supplement_2","key":"2025022111124485100_qxaf016-B13","doi-asserted-by":"publisher","first-page":"ofad500.059","DOI":"10.1093\/ofid\/ofad500.059","article-title":"1028. Real-world use of long-acting cabotegravir + rilpivirine in people with HIV with detectable viral loads at initiation: findings from the OPERA\u00ae cohort","volume":"10","author":"Hsu","year":"2023","journal-title":"Open Forum Infect Dis."},{"key":"2025022111124485100_qxaf016-B14","article-title":"Ryan White HIV\/AIDS Treatment Modernization Act, 31 U.S.C. \u00a7 7502 (2006). Vol 6143","year":"2006"},{"key":"2025022111124485100_qxaf016-B15","article-title":"AIDS Drug Assistance Program performance measures","author":"Health Resources and Services Administration","year":"2024"},{"issue":"9","key":"2025022111124485100_qxaf016-B16","doi-asserted-by":"publisher","first-page":"ofac455","DOI":"10.1093\/ofid\/ofac455","article-title":"Early experience implementing long-acting injectable cabotegravir\/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White-Funded Clinic in the US South","volume":"9","author":"Collins","year":"2022","journal-title":"Open Forum Infect Dis."},{"issue":"12","key":"2025022111124485100_qxaf016-B17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/aid.2024.0007","article-title":"Early implementation and outcomes among people with HIV who accessed long-acting injectable Cabotegravir\/Rilpivirine at Two Ryan White Clinics in the U.S. South","volume":"40","author":"Haser","year":"2024","journal-title":"AIDS Res Hum Retroviruses."},{"issue":"2","key":"2025022111124485100_qxaf016-B18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/apc.2023.0248","article-title":"Long-acting injectable antiretrovirals for HIV treatment: a multi-site qualitative study of clinic-level barriers to implementation in the United States","volume":"38","author":"McCrimmon","year":"2024","journal-title":"AIDS Patient Care STDS."},{"key":"2025022111124485100_qxaf016-B19","author":"Medicaid and CHIP Payment and Access Commission"},{"key":"2025022111124485100_qxaf016-B20","author":"Crowley"},{"key":"2025022111124485100_qxaf016-B21","author":"ViiV Healthcare"},{"issue":"7","key":"2025022111124485100_qxaf016-B22","doi-asserted-by":"publisher","first-page":"331","DOI":"10.37765\/ajmc.2023.89394","article-title":"Influence of prior authorization requirements on provider clinical decision making","volume":"29","author":"Salzbrenner","year":"2023","journal-title":"Am J Manag Care"},{"issue":"Supplement_4","key":"2025022111124485100_qxaf016-B23","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","article-title":"Barriers to uptake of long-acting antiretroviral products for treatment and prevention of Human Immunodeficiency Virus (HIV) in high-income countries","volume":"75","author":"Cooper","year":"2022","journal-title":"Clin Infect Dis."},{"issue":"S1","key":"2025022111124485100_qxaf016-B24","doi-asserted-by":"publisher","first-page":"e26282","DOI":"10.1002\/jia2.26282","article-title":"Long-acting injectable ART to advance health equity: a descriptive analysis of US clinic perspectives on barriers, needed support and programme goals for implementation from applications to the ALAI UP project","volume":"27","author":"Nguyen","year":"2024","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"2025022111124485100_qxaf016-B25","first-page":"474","article-title":"Savings on high-cost drugs such as atypical long-acting injectable antipsychotics: switching to billing under the pharmacy benefit in outpatient settings","volume":"44","author":"Budovich","year":"2019","journal-title":"P T"},{"issue":"11","key":"2025022111124485100_qxaf016-B26","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/acr.24062","article-title":"Treatment delays associated with prior authorization for infusible medications: a cohort study","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2025022111124485100_qxaf016-B27"},{"issue":"9","key":"2025022111124485100_qxaf016-B28","doi-asserted-by":"publisher","first-page":"e26003","DOI":"10.1002\/jia2.26003","article-title":"Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE)","volume":"25","author":"Czarnogorski","year":"2022","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"2025022111124485100_qxaf016-B29","doi-asserted-by":"publisher","first-page":"ofad341","DOI":"10.1093\/ofid\/ofad341","article-title":"Acceptability, feasibility, and appropriateness of implementation of long-acting injectable antiretrovirals: a national survey of Ryan White Clinics in the United States","volume":"10","author":"Tarfa","year":"2023","journal-title":"Open Forum Infect Dis."},{"key":"2025022111124485100_qxaf016-B30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/QAI.0000000000003421","article-title":"Identifying implementation determinants and strategies for long-acting injectable cabotegravir-rilpivirine in people with HIV who are virally unsuppressed","volume":"96","author":"Hickey","year":"2024","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxaf016\/61666781\/qxaf016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/2\/qxaf016\/61666781\/qxaf016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/2\/qxaf016\/61666781\/qxaf016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:14:17Z","timestamp":1740136457000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxaf016\/7985951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxaf016","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,29]]},"article-number":"qxaf016"}}